TEMALIEVA 250MG ( Temozolomide Capsules IP 250mg )

TEMALIEVA 250 mg contains Temozolomide, an oral alkylating chemotherapy agent. It damages tumor cell DNA by methylation, leading to inhibition of DNA replication and cell death. Because it crosses the blood–brain barrier, it is especially effective for malignant brain tumors.

Temozolomide is used in the treatment of:

1.  Glioblastoma multiforme (GBM)
     – Newly diagnosed (with radiotherapy) and recurrent disease

2.  Anaplastic astrocytoma

3.  Other high-grade gliomas (as per oncology protocol)

Common side effects:

•   Nausea and vomiting

•   Fatigue

•   Constipation or diarrhea

•   Headache

•   Loss of appetite

Hematological side effects:

•   Neutropenia

•   Thrombocytopenia

•   Anemia

Serious side effects:

•   Severe myelosuppression

•   Opportunistic infections (e.g., Pneumocystis jirovecii pneumonia)

•   Elevated liver enzymes

CBC and liver function tests should be monitored regularly.

Dose is calculated based on body surface area (BSA) and treatment phase.

Standard regimens:

1.  Concomitant with radiotherapy (GBM):

     • 75 mg/m² once daily for 42 days

2. Adjuvant / maintenance therapy:

     • 150–200 mg/m² once daily for 5 days every 28-day cycle

250 mg capsules are used for higher daily dose requirements.


NOTE: This medicine should be taken only under a doctor’s supervision.